Dr. Kumar: Results of the ENDURANCE Trial Support Standard of Care Treatment for Myeloma

ENDURANCE trial: KRd versus VRd for initial therapy of NDMMПодробнее

What are the results from the ENDURANCE trial that compares KRd to VRd in newly diagnosed patients?Подробнее

Dr. Kumar on Treatment Discontinuation in the ENDURANCE Myeloma TrialПодробнее

Dr. Kumar on Takeaways From the ENDURANCE Trial in Multiple MyelomaПодробнее

Dr. Kumar on the Results of the ASPIRE TrialПодробнее

Shaji Kumar, MD, shares results of the Phase 3 study regarding 1st line multiple myeloma treatmentПодробнее

Shaji Kumar: Comparing KRd With VRd in Newly Diagnosed MyelomaПодробнее

Shaji Kumar, ASCO20: Efficacy and Toxicity in the Randomised Phase III ENDURANCE Trial in MyelomaПодробнее

Should Frontline Myeloma Treatment Include a 3- or 4-Drug Regimen?Подробнее

Dr. Kumar on the Management of Newly Diagnosed Patients With Multiple MyelomaПодробнее

A Look at the ENDURANCE TrialПодробнее

Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art CareПодробнее

Results of ENDURANCE (E1A11) phase III trial: KRd versus VRd for initial therapy of NDMMПодробнее

Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myelomaПодробнее

Dr. Kumar Dr. Kumar Discusses the Role of Stem Cell Transplant in Multiple MyelomaПодробнее

Can daratumumab be used to treat refractory MM?Подробнее

Dr. Raje on the Design of the ENDURANCE Trial in Newly Diagnosed Multiple MyelomaПодробнее

ENDURANCE: RVD vs KrD for myelomaПодробнее

Additional Advances in Multiple Myeloma Research and Clinical Trials With Shaji Kumar, MDПодробнее